Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The form provides key information about the dealings of the exempt principal trader with recognized intermediary status. The form states that Panmure Gordon (UK) Limited has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The form also mentions that there have been no cash-settled derivative transactions or stock-settled derivative transactions, including options, involving Allergy Therapeutics' securities. Additionally, there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities, options, or derivatives. The disclosure was made on August 31, 2023, and the contact person for further information is Freddie Wooding at +44 (0)20 7886 2969.